Wall Street brokerages forecast that TESARO Inc (NASDAQ:TSRO) will post $51.78 million in sales for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for TESARO’s earnings, with estimates ranging from $46.07 million to $59.17 million. TESARO posted sales of $4.23 million in the same quarter last year, which would indicate a positive year over year growth rate of 1,124.1%. The company is scheduled to announce its next earnings report after the market closes on Tuesday, February 27th.
On average, analysts expect that TESARO will report full-year sales of $51.78 million for the current financial year, with estimates ranging from $221.37 million to $299.10 million. For the next fiscal year, analysts anticipate that the firm will post sales of $388.01 million per share, with estimates ranging from $274.00 million to $529.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for TESARO.
Several analysts recently commented on TSRO shares. Robert W. Baird reaffirmed a “hold” rating and set a $120.00 target price on shares of TESARO in a report on Friday, November 10th. Leerink Swann raised TESARO from a “market perform” rating to an “outperform” rating in a report on Wednesday, November 15th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $65.00 target price on shares of TESARO in a report on Thursday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 target price on shares of TESARO in a report on Monday, November 20th. Finally, Barclays started coverage on TESARO in a report on Monday, October 23rd. They set an “equal weight” rating and a $135.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. TESARO currently has a consensus rating of “Hold” and a consensus price target of $149.97.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 34.60% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC boosted its position in TESARO by 8.1% during the third quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after purchasing an additional 29,100 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of TESARO in the third quarter valued at approximately $33,911,000. California State Teachers Retirement System lifted its position in shares of TESARO by 20.8% in the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after acquiring an additional 11,706 shares in the last quarter. Voya Investment Management LLC lifted its position in shares of TESARO by 22.9% in the second quarter. Voya Investment Management LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $2,001,000 after acquiring an additional 2,667 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its position in shares of TESARO by 379.4% in the third quarter. Vident Investment Advisory LLC now owns 5,652 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 4,473 shares in the last quarter.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.